These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 19887548)

  • 1. CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo.
    Burns CJ; Fantino E; Phillips ID; Su S; Harte MF; Bukczynska PE; Frazzetto M; Joffe M; Kruszelnicki I; Wang B; Wang Y; Wilson N; Dilley RJ; Wan SS; Charman SA; Shackleford DM; Fida R; Malcontenti-Wilson C; Wilks AF
    Mol Cancer Ther; 2009 Nov; 8(11):3036-45. PubMed ID: 19887548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The microtubule depolymerizing agent CYT997 causes extensive ablation of tumor vasculature in vivo.
    Burns CJ; Fantino E; Powell AK; Shnyder SD; Cooper PA; Nelson S; Christophi C; Malcontenti-Wilson C; Dubljevic V; Harte MF; Joffe M; Phillips ID; Segal D; Wilks AF; Smith GD
    J Pharmacol Exp Ther; 2011 Dec; 339(3):799-806. PubMed ID: 21917561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of CYT997: a structurally novel orally active microtubule targeting agent.
    Burns CJ; Harte MF; Bu X; Fantino E; Joffe M; Sikanyika H; Su S; Tranberg CE; Wilson N; Charman SA; Shackleford DM; Wilks AF
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4639-42. PubMed ID: 19616947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYT997(Lexibulin) induces apoptosis and autophagy through the activation of mutually reinforced ER stress and ROS in osteosarcoma.
    Wang Z; Yin F; Xu J; Zhang T; Wang G; Mao M; Wang Z; Sun W; Han J; Yang M; Jiang Y; Hua Y; Cai Z
    J Exp Clin Cancer Res; 2019 Jan; 38(1):44. PubMed ID: 30704503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity.
    Teng Y; Cai Y; Pi W; Gao L; Shay C
    J Hematol Oncol; 2017 Jun; 10(1):118. PubMed ID: 28606127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agent.
    Burge M; Francesconi AB; Kotasek D; Fida R; Smith G; Wilks A; Vasey PA; Lickliter JD
    Invest New Drugs; 2013 Feb; 31(1):126-35. PubMed ID: 22451157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer.
    Li CM; Lu Y; Chen J; Costello TA; Narayanan R; Dalton MN; Snyder LM; Ahn S; Li W; Miller DD; Dalton JT
    Pharm Res; 2012 Nov; 29(11):3053-63. PubMed ID: 22760659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autophagy blockade sensitizes human head and neck squamous cell carcinoma towards CYT997 through enhancing excessively high reactive oxygen species-induced apoptosis.
    Gao L; Zhao X; Lang L; Shay C; Andrew Yeudall W; Teng Y
    J Mol Med (Berl); 2018 Sep; 96(9):929-938. PubMed ID: 30022281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells.
    Yan J; Pang Y; Sheng J; Wang Y; Chen J; Hu J; Huang L; Li X
    Biochem Pharmacol; 2015 Sep; 97(1):51-61. PubMed ID: 26212540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYT997 causes apoptosis in human multiple myeloma.
    Monaghan K; Khong T; Smith G; Spencer A
    Invest New Drugs; 2011 Apr; 29(2):232-8. PubMed ID: 19907921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer.
    Ahn S; Hwang DJ; Barrett CM; Yang J; Duke CB; Miller DD; Dalton JT
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):293-304. PubMed ID: 20383708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DAT-230, a novel microtubule inhibitor, exhibits potent anti-tumor activity by inducing G2/M phase arrest, apoptosis in vitro and perfusion decrease in vivo to HT-1080.
    Qiao F; Zuo D; Shen X; Qi H; Wang H; Zhang W; Wu Y
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):259-70. PubMed ID: 22752214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, antitumor activities and biological studies of novel diaryl substituted fused heterocycles as dual ligands targeting tubulin and katanin.
    Gao F; Liang Y; Zhou P; Cheng J; Ding K; Wang Y
    Eur J Med Chem; 2019 Sep; 178():177-194. PubMed ID: 31185410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenoxodiol inhibits growth of metastatic prostate cancer cells.
    Aguero MF; Venero M; Brown DM; Smulson ME; Espinoza LA
    Prostate; 2010 Aug; 70(11):1211-21. PubMed ID: 20564423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. YSL-12, a novel microtubule-destabilizing agent, exerts potent anti-tumor activity against colon cancer in vitro and in vivo.
    Cai D; Qiu Z; Yao W; Liu Y; Huang H; Liao S; Luo Q; Xie L; Lin Z
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1217-29. PubMed ID: 27107592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DAT-230, a Novel Microtubule Inhibitor, Induced Aberrant Mitosis and Apoptosis in SGC-7901 Cells.
    Qiao F; Zuo D; Wang H; Li Z; Qi H; Zhang W; Wu Y
    Biol Pharm Bull; 2013; 36(2):193-201. PubMed ID: 23370351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyrrolotetrazinones deazaanalogues of temozolomide induce apoptosis in Jurkat cell line: involvement of tubulin polymerization inhibition.
    Viola G; Cecconet L; Leszl A; Basso G; Brun P; Salvador A; Dall'Acqua F; Diana P; Barraja P; Cirrincione G
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1235-51. PubMed ID: 19363609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
    Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA
    Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent.
    Lickliter JD; Francesconi AB; Smith G; Burge M; Coulthard A; Rose S; Griffin M; Milne R; McCarron J; Yeadon T; Wilks A; Cubitt A; Wyld DK; Vasey PA
    Br J Cancer; 2010 Aug; 103(5):597-606. PubMed ID: 20733579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Desacetylvinblastine Monohydrazide Disrupts Tumor Vessels by Promoting VE-cadherin Internalization.
    Lei X; Chen M; Huang M; Li X; Shi C; Zhang D; Luo L; Zhang Y; Ma N; Chen H; Liang H; Ye W; Zhang D
    Theranostics; 2018; 8(2):384-398. PubMed ID: 29290815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.